In this open-label study, 260 people with relapsing forms of MS??? injected 44 mcg of Rebif under the skin three times weekly, and the results were compared with historical data from the previously completed EVIDENCE study (in which the original Rebif was compared toAvonex??-- interferon beta 1a, Biogen Idec).